TY - JOUR
T1 - Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas
AU - Wagner-Johnston, Nina D.
AU - Schuster, Stephen J.
AU - deVos, Sven
AU - Salles, Gilles
AU - Jurczak, Wojciech J.
AU - Flowers, Christopher R.
AU - Viardot, Andreas
AU - Flinn, Ian W.
AU - Martin, Peter
AU - Xing, Guan
AU - Rajakumaraswamy, Nishanthan
AU - Gopal, Ajay K.
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - The phase 2 study of idelalisib monotherapy for indolent non-Hodgkin lymphomas (iNHLs) was completed in 2018; final efficacy and safety data with up to 6.7 years long-term follow-up are reported. Patients with iNHL refractory to both rituximab and an alkylating agent were enrolled and received 150 mg idelalisib twice daily (N = 125). Idelalisib resulted in an overall response rate of 57.6% with 34.4% continuing therapy for ≥12 months. The median progression-free survival and duration of response were 11.0 and 11.8 months for follicular lymphoma, 22.2 and 20.4 months for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM), and 6.6 and 18.4 months for marginal zone lymphoma (MZL). Median overall survival after extended follow-up was 48.6 (95% CI 33.9, 71.7) months. Long-term follow-up did not reveal new safety concerns. These data indicate beneficial outcomes with longer follow-up after idelalisib for treatment of iNHL including in patients with LPL/WM and MZL.
AB - The phase 2 study of idelalisib monotherapy for indolent non-Hodgkin lymphomas (iNHLs) was completed in 2018; final efficacy and safety data with up to 6.7 years long-term follow-up are reported. Patients with iNHL refractory to both rituximab and an alkylating agent were enrolled and received 150 mg idelalisib twice daily (N = 125). Idelalisib resulted in an overall response rate of 57.6% with 34.4% continuing therapy for ≥12 months. The median progression-free survival and duration of response were 11.0 and 11.8 months for follicular lymphoma, 22.2 and 20.4 months for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM), and 6.6 and 18.4 months for marginal zone lymphoma (MZL). Median overall survival after extended follow-up was 48.6 (95% CI 33.9, 71.7) months. Long-term follow-up did not reveal new safety concerns. These data indicate beneficial outcomes with longer follow-up after idelalisib for treatment of iNHL including in patients with LPL/WM and MZL.
KW - Idelalisib
KW - PI3K inhibitor
KW - Waldenström’s macroglobulinemia
KW - follicular lymphoma
KW - indolent non-Hodgkin lymphoma
KW - marginal zone lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85102920754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102920754&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1855344
DO - 10.1080/10428194.2020.1855344
M3 - Article
C2 - 33300385
AN - SCOPUS:85102920754
SN - 1042-8194
VL - 62
SP - 1077
EP - 1087
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -